CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
CBAY Stock Price Chart Interactive Chart >
CBAY Price/Volume Stats
| Current price | $2.95 | 52-week high | $4.74 |
| Prev. close | $2.85 | 52-week low | $1.67 |
| Day low | $2.72 | Volume | 524,800 |
| Day high | $2.97 | Avg. volume | 609,619 |
| 50-day MA | $2.19 | Dividend yield | N/A |
| 200-day MA | $3.16 | Market Cap | 249.80M |
CymaBay Therapeutics Inc. (CBAY) Company Bio
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.
Latest CBAY News From Around the Web
Below are the latest news stories about CymaBay Therapeutics Inc that investors may wish to consider to help them evaluate CBAY as an investment opportunity.
CymaBay Therapeutics to Present at Upcoming Investor ConferencesNEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in two virtual investor conferences including the 11th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022. 11t |
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.Although Albireo (ALBO) has an attractive and robust pipeline, I have focused mainly on Odevixibat in my articles so far. In my opinion, this is right, as the approved and revenue generating product Bylvay (Odevixibat in PFIC) is currently the biggest value driver for Albireo and actually justifies more than... |
LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ...Investment company LCM Capital Management Inc (Current Portfolio) buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Duke Energy Corp, Xcel Energy Inc, sells Tesla Inc, Biogen Inc, Yum China Holdings Inc, UiPath Inc, CymaBay Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LCM Capital Management Inc. |
Trade Alert: The Chief Medical Officer Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Dennis Kim, Has Just Spent US$61k Buying A Few More SharesEven if it's not a huge purchase, we think it was good to see that Dennis Kim, the Chief Medical Officer of CymaBay... |
CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the UpgradeCymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
CBAY Price Returns
| 1-mo | 48.24% |
| 3-mo | -9.79% |
| 6-mo | -12.72% |
| 1-year | -33.26% |
| 3-year | -58.04% |
| 5-year | -48.78% |
| YTD | -12.72% |
| 2021 | -41.11% |
| 2020 | 192.86% |
| 2019 | -75.10% |
| 2018 | -14.46% |
| 2017 | 431.79% |
Loading social stream, please wait...